Pembrolizumab Datasheet DC Chemicals
Description Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.
Cat.No A016
Name Pembrolizumab

Chemical Properties

CAS 1374853-91-4
Synonyms Pembrolizumab;Keytruda;Lambrolizumab;Lanbrolizumab;MK 3475;Merck 3475;1374853-91-4;DA-76698;DA-76698;1-butyl-4-propylpiperazine;ethane;1-[hex-5-enyl(2-methyltetradecyl)amino]tetradecan-2-ol;3-[[(8E,10E)-2-methylhexadeca-8,10-dienyl]-[(9E,11E)-2-methylhexadeca-9,11-dienyl]amino]propane-1-thiol;1-butyl-4-propylpiperazine;ethane;1-[hex-5-enyl(2-methyltetradecyl)amino]tetradecan-2-ol;3-[[(8E,10E)-2-methylhexadeca-8,10-dienyl]-[(9E,11E)-2-methylhexadeca-9,11-dienyl]amino]propane-1-thiol
pH value Corresponds to reference standard： PASS
Non-reduced CE-SDS 98.1%
SEC-HPLC 99.7%
Isoelectric Point Corresponds to reference standard:PASS
Bacterial Endotoxins Test ＜1 EU/ml
Residual Proteins of Host Cell
Exogenous Residual DNA ＜1 pg/mg
Residual protein A ＜1 ng/mg
Biological Activity Compared with standard, the range of biological activity is 113%
Osmolality Corresponds to reference standard: PASS
Peptide mapping Corresponds to reference standard: PASS
N-terminal sequence Corresponds to reference standard:PASS

References

[1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com